My ePortfolio Register   

FDA grants regular approval to nivolumab for adjuvant treatment of melanoma

On December 20, 2017, the U.S. Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, nivolumab for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection.

Nivolumab was previously approved for the treatment of patients with unresectable or metastatic melanoma.

Approval was based on improvement in recurrence-free survival (RFS) in a randomized, double-blind trial, CHECKMATE-238 (NCT02388906), in 906 patients with completely resected, Stage IIIB/C or Stage IV (AJCC 7th ed) melanoma.

Patients were randomly allocated (1:1) to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses then every 12 weeks beginning at Week 24 for up to 1 year.

Enrollment required complete resection of melanoma with margins negative for disease within 12 weeks prior to randomization.

The major efficacy outcome measure was RFS, defined as the time between the randomization date and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma, or death from any cause, whichever occurs first.

Patients in the nivolumab arm experienced fewer recurrences/deaths, 34% (n=154), compared with 45.5% (n=206) in the ipilimumab arm (hazard ratio 0.65; 95% confidence interval 0.53, 0.80; p<0.0001). Median RFS was not reached on either arm.

The median duration of nivolumab exposure was 11.5 months and 74% of patients received nivolumab for greater than 6 months.

Nivolumab was discontinued for adverse reactions in 9% of patients.

The most common adverse reactions (reported in at least 20% of nivolumab-treated patients in CHECKMATE-238) were fatigue, diarrhoea, rash, musculoskeletal pain, pruritus, headache, nausea, upper respiratory infection, and abdominal pain.

The most common immune-mediated adverse reactions were rash (16%), diarrhoea/colitis (6%), and hepatitis (3%).

Source: FDA




Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence